

# Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015

<https://marketpublishers.com/r/CA1EC72D2FBEN.html>

Date: August 2015

Pages: 600

Price: US\$ 3,000.00 (Single User License)

ID: CA1EC72D2FBEN

## Abstracts

**Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.**

Pharmaceutical companies are continuously looking for better therapeutic options to effectively cure and prevent various malignancies. Several options for cancer treatment are available belonging to various classes of molecules. Different types of cancer have different pathophysiological characteristics due to which distinctive approach is required for effective treatment. Several molecules have been discovered out of which CD antigens have been found to play an important role in cancer progression and proliferation. Investigators are trying to assign different functions to CD antigens by doing extensive research and development. Their role in cancer development has been noted due to which lots of progress would be observed in this segment. Most of the work has been done in cancer segment and pharmacological profiles are expected to be improved in coming years.

CD antigen cancer therapeutics have diverse design and target due to which they could be used for several malignancies. Presence of BiTEs, ADC, monoclonal antibodies and tri-functional antibodies for targeting different CD antigens has been commercialized. Next step is assumed to be the improvement in design as complexity at molecular levels makes it difficult to manufacture them in large quantities. This issue not only decreases the productivity but also increases the cost of production. Higher cost of end products limits the number of cancer patients choosing them as a part of their regular therapeutic regime. With the use of advanced technology it is expected that this issue would be overcome in coming years. Some of the progress could be observed in case of monoclonal antibodies and same scenario could be observed for other CD antigen cancer therapeutics in coming years.

Clinical trials are being instigated across the globe in order to extend their utilities in different malignancies. They are versatile in nature due to which they could be used as a part of combinatorial therapy along with monoclonal antibodies. Their utilities in different malignancies are also being studied but results of such clinical trials remains elusive. They have strong clinical pipeline due to which several products would be introduced in coming years. However, these products are at different stages of clinical pipeline and they may take long winding times as lots of experiments proving their safety and efficacy has to be done. With time more CD antigens are expected to be discovered and they would help in the increased market size. Commercial success of marketed CD antigen cancer therapeutics shows that they would be generating significant revenues in coming years.

CD antigen cancer market is expected to witness introduction of several products which will help the pharmaceutical companies to generate significant revenues. Increasing demand for better therapeutics, large unmet medical necessities and large numbers of cancer patient's patient are expected to be responsible for the growth of this market segment. Increased funding in research and development along with utilization of advanced technology will also help in increasing their market shares across the globe. Numerous innovative CD antigen cancer therapeutics are at different stages of clinical trials which would increase their market shares. Despite these facts they have higher prices and their manufacturing is difficult but utilization of advanced technology along with streamlining of various processes are expected to overcome this barrier. In this way, future of CD antigen cancer therapeutics looks optimistic due to their superior pharmacological profiles.

#### CD Antigens Segments in Report:

CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52, CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279

#### "Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015" Report Highlight:

Nomenclature & Classification of CD Antigens

Mechanism of CD Antigen Cancer Therapeutics

Cancer CD Antigen Therapy Market Overview

Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs

Marketed Cancer CD Antigen Inhibitors: 27 Drugs

Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs

Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 44 Drugs

Cancer CD Antigens Clinical Pipeline is Represented in 52 Graphs & Charts

## Contents

### **1. INTRODUCTION TO CD ANTIGENS**

### **2. NOMENCLATURE & CLASSIFICATION OF CD ANTIGENS**

### **3. MECHANISM OF CD ANTIGEN CANCER THERAPEUTICS**

### **4. CANCER CD ANTIGEN THERAPY MARKET OVERVIEW**

#### **4.1 Current Scenario**

#### **4.2 Cancer CD Antigen Inhibitors Pipeline Overview**

### **5. CD ANTIGEN CANCER MARKET DYNAMICS**

#### **5.1 Favorable Market Parameters**

#### **5.2 Commercialization Challenges**

### **6. CD ANTIGEN CANCER THERAPEUTICS FUTURE PROSPECTS**

### **7. CANCER CD ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### **7.1 Phase-I/II**

### **8. CANCER CD3 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### **8.1 Preclinical till Phase-II**

### **9. CANCER CD4 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### **9.1 Phase-II**

### **10. CANCER CD9 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

## 10.1 Preclinical

### **11. CANCER CD11 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 11.1 Preclinical

### **12. CANCER CD19 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 12.1 Phase-I till Phase-II

### **13. CANCER CD20 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 13.1 Research till Phase-III

#### 13.2 Marketed CD20 Antigen Inhibitors Drug Clinical Insight

### **14. CANCER CD22 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 14.1 Phase-II till Phase-III

### **15. CANCER CD26 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 15.1 Preclinical till Phase-I/II

### **16. CANCER CD27 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 16.1 Research till Phase-I/II

### **17. CANCER CD28 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 17.1 Preclinical

### **18. CANCER CD29 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY,**

**INDICATION & PHASE**

18.1 Preclinical

**19. CANCER CD33 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

19.1 Phase-I till Phase-I/II

19.2 Marketed CD33 Antigen Inhibitors Drug Clinical Insight

**20. CANCER CD37 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

20.1 Phase-I till Phase-II

**21. CANCER CD38 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

21.1 Research till Preregistration

**22. CANCER CD40 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

22.1 Phase-I

**23. CANCER CD44 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

23.1 Preclinical

**24. CANCER CD45 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

24.1 Preclinical till Phase-II

**25. CANCER CD47 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

25.1 Preclinical till Phase-I

**26. CANCER CD52 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

26.1 Research till Preclinical

26.2 Marketed CD52 Antigen Inhibitors Drug Clinical Insight

**27. CANCER CD55 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

27.1 Preclinical till Phase-II

**28. CANCER CD56 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

28.1 Preclinical till Phase-II

**29. CANCER CD66 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

29.1 Preclinical till Phase-II

**30. CANCER CD70 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

30.1 Phase-I

**31. CANCER CD74 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

31.1 Preclinical till Phase-I/II

**32. CANCER CD80 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

32.1 Preclinical till Phase-II

**33. CANCER CD95 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

33.1 Preclinical

#### **34. CANCER CD98 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

34.1 Phase-I

#### **35. CANCER CD100 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

35.1 Phase-I

#### **36. CANCER CD117 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

36.1 Preclinical till Phase-III

36.2 Marketed CD117 Antigen Inhibitors Drug Clinical Insight

#### **37. CANCER CD135 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

37.1 Preclinical till Phase-III

37.2 Marketed CD135 Antigen Inhibitors Drug Clinical Insight

#### **38. CANCER CD137 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

38.1 Preclinical

#### **39. CANCER CD152 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

39.1 Marketed CD152 Antigen Inhibitors Drug Clinical Insight

#### **40. CANCER CD200 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

40.1 Preclinical



#### **41. CANCER CD223 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

41.1 Research till Phase-I

#### **42. CANCER CD227 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

42.1 Phase-I till Phase-II

#### **43. CANCER CD246 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

43.1 Preclinical till Phase-II

43.2 Marketed CD246 Antigen Inhibitors Drug Clinical Insight

#### **44. CANCER CD248 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

44.1 Phase-II

#### **45. CANCER CD274 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

45.1 Research till Phase-III

45.2 Marketed CD274 Antigen Inhibitors Drug Clinical Insight

#### **46. CANCER CD276 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

46.1 Phase-I

#### **47. CANCER CD279 ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

47.1 Phase-I till Phase-II

47.2 Marketed CD279 Antigen Inhibitors Drug Clinical Insight

## **48. MULTIPLE CANCER CD ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

48.1 Preclinical till Phase-III

48.2 Marketed Multiple CD Antigen Inhibitors Drug Clinical Insight

## **49. DISCONTINUED & SUSPENDED CANCER CD ANTIGEN INHIBITORS DRUG CLINICAL INSIGHT**

49.1 No Development Reported

49.2 Discontinued

49.3 Market Withdrawal

49.4 Suspended

## **50. COMPETITIVE LANDSCAPE**

50.1 Alexion Pharmaceuticals

50.2 ARIAD Pharmaceuticals

50.3 AryoGen Biopharma

50.4 AXXO

50.5 Bayer HealthCare

50.6 Biocad

50.7 Biogen

50.8 Biotechnol Inc.

50.9 Bristol-Myers Squibb

50.10 Chugai Pharmaceutical

50.11 Dr Reddy's Laboratories

50.12 Eisai Co Ltd

50.13 Emergent BioSolutions

50.14 Genmab

50.15 ImmunoGen

50.16 Intas Biopharmaceuticals

50.17 MacroGenics

50.18 MedImmune

50.19 Merck

50.20 Novartis

50.21 Ono Pharmaceutical

50.22 Onyx Pharmaceuticals

50.23 Pfizer

50.24 PROBIOMED

50.25 Roche

50.26 UCB

50.27 Xencor

## List Of Figures

### LIST OF FIGURES

Figure 1-1: Functions of CD Antigens

Figure 1-2: Properties of CD Antigens

Figure 2-1: Types of WBC

Figure 2-2: Classification of CD Antigens

Figure 3-1: Important Features of CD Antigens

Figure 3-2: Mechanism of Rituximab

Figure 3-3: Mechanism of Brentuximab Vedotin

Figure 3-4: Mechanism of Blinatumomab

Figure 3-5: Mechanism of Ibritumomab Tiuxetan

Figure 3-6: Mechanism of Tositumomab Iodine

Figure 3-7: Mechanism of Catumaxomab

Figure 4-1: Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2015

Figure 4-2: Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2015

Figure 4-3: Cancer CD3 Antigen Pipeline by Phase (%), 2015

Figure 4-4: Cancer CD3 Antigen Pipeline by Phase (Number), 2015

Figure 4-5: Cancer CD19 Antigen Pipeline by Phase (%), 2015

Figure 4-6: Cancer CD19 Antigen Pipeline by Phase (Number), 2015

Figure 4-7: Cancer CD20 Antigen Pipeline by Phase (%), 2015

Figure 4-8: Cancer CD20 Antigen Pipeline by Phase (Number), 2015

Figure 4-9: Cancer CD22 Antigen Pipeline by Phase (%), 2015

Figure 4-10: Cancer CD22 Antigen Pipeline by Phase (Number), 2015

Figure 4-11: Cancer CD26 Antigen Pipeline by Phase (%), 2015

Figure 4-12: Cancer CD26 Antigen Pipeline by Phase (Number), 2015

Figure 4-13: Cancer CD27 Antigen Pipeline by Phase (%), 2015

Figure 4-14: Cancer CD27 Antigen Pipeline by Phase (Number), 2015

Figure 4-15: Cancer CD33 Antigen Pipeline by Phase (%), 2015

Figure 4-16: Cancer CD33 Antigen Pipeline by Phase (Number), 2015

Figure 4-17: Cancer CD38 Antigen Pipeline by Phase (%), 2015

Figure 4-18: Cancer CD38 Antigen Pipeline by Phase (Number), 2015

Figure 4-19: Cancer CD45 Antigen Pipeline by Phase (%), 2015

Figure 4-20: Cancer CD45 Antigen Pipeline by Phase (Number), 2015

Figure 4-21: Cancer CD47 Antigen Pipeline by Phase (%), 2015

Figure 4-22: Cancer CD47 Antigen Pipeline by Phase (Number), 2015

Figure 4-23: Cancer CD52 Antigen Pipeline by Phase (%), 2015

Figure 4-24: Cancer CD52 Antigen Pipeline by Phase (Number), 2015

- Figure 4-25: Cancer CD55 Antigen Pipeline by Phase (%), 2015
- Figure 4-26: Cancer CD55 Antigen Pipeline by Phase (Number), 2015
- Figure 4-27: Cancer CD56 Antigen Pipeline by Phase (%), 2015
- Figure 4-28: Cancer CD56 Antigen Pipeline by Phase (Number), 2015
- Figure 4-29: Cancer CD66 Antigen Pipeline by Phase (%), 2015
- Figure 4-30: Cancer CD66 Antigen Pipeline by Phase (Number), 2015
- Figure 4-31: Cancer CD74 Antigen Pipeline by Phase (%), 2015
- Figure 4-32: Cancer CD74 Antigen Pipeline by Phase (Number), 2015
- Figure 4-33: Cancer CD80 Antigen Pipeline by Phase (%), 2015
- Figure 4-34: Cancer CD80 Antigen Pipeline by Phase (Number), 2015
- Figure 4-35: Cancer CD117 Antigen Pipeline by Phase (%), 2015
- Figure 4-36: Cancer CD117 Antigen Pipeline by Phase (Number), 2015
- Figure 4-37: Cancer CD135 Antigen Pipeline by Phase (%), 2015
- Figure 4-38: Cancer CD135 Antigen Pipeline by Phase (Number), 2015
- Figure 4-39: Cancer CD223 Antigen Pipeline by Phase (%), 2015
- Figure 4-40: Cancer CD223 Antigen Pipeline by Phase (Number), 2015
- Figure 4-41: Cancer CD227 Antigen Pipeline by Phase (%), 2015
- Figure 4-42: Cancer CD227 Antigen Pipeline by Phase (Number), 2015
- Figure 4-43: Cancer CD246 Antigen Pipeline by Phase (%), 2015
- Figure 4-44: Cancer CD246 Antigen Pipeline by Phase (Number), 2015
- Figure 4-45: Multiple Cancer CD Antigen Pipeline by Phase (%), 2015
- Figure 4-46: Multiple Cancer CD Antigen Pipeline by Phase (Number), 2015
- Figure 4-47: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (%), 2015
- Figure 4-48: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (Number), 2015
- Figure 4-49: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (%), 2015
- Figure 4-50: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (Number), 2015
- Figure 4-51: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (%), 2015
- Figure 4-52: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (Number), 2015
- Figure 5-1: Favorable Market Features
- Figure 5-2: Cancer CD Antigen Inhibitors Commercialization Challenges

## List Of Tables

### LIST OF TABLES

Table 5-1: Different CD Antigens used for Hematological Malignancies

### COMPANIES MENTIONED

Alexion Pharmaceuticals  
ARIAD Pharmaceuticals  
AryoGen Biopharma  
AXXO  
Bayer HealthCare  
Biocad  
Biogen  
Biotechnol Inc.  
Bristol-Myers Squibb  
Chugai Pharmaceutical  
Dr Reddy's Laboratories  
Eisai Co Ltd  
Emergent BioSolutions  
Genmab  
ImmunoGen  
Intas Biopharmaceuticals  
MacroGenics  
MedImmune  
Merck  
Novartis  
Ono Pharmaceutical  
Onyx Pharmaceuticals  
Pfizer  
PROBIOMED  
Roche  
UCB  
Xencor

## I would like to order

Product name: Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015

Product link: <https://marketpublishers.com/r/CA1EC72D2FBEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA1EC72D2FBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970